Quantitative SPECT/CT dosimetry in [ 177 Lu]Lutetiumvipivotide tetraxetan therapy is system-dependent despite phantom calibration: implications for multicenter studies (EANM 2026) - Sep 29, 2026 - Abstract #EP-1240; "Aim/Introduction: Quantitative SPECT/CT is increasingly used for dosimetry in [177Lu]Lutetium-vipivotide tetraxetan ([177Lu]LuPSMA) radioligand therapy (RLT), with phantom-based calibration recommended to ensure accuracy and comparability across imaging systems... Quantitative SPECT/CT-based dosimetry in [177Lu]LuPSMA therapy remains dependent on the imaging system despite phantom calibration. These findings indicate that phantom-based calibration alone is insufficient to ensure clinical comparability of dosimetric estimates. This has direct implications for multicenter studies and for the transferability of dose-toxicity relationships, highlighting the need for harmonization or correction strategies before applying universal dosimetric thresholds in clinical practice."
Clinical
|
|
Y. Cras 1; J. T. Donoso Jaurès 2, 1; H. Noamen 1; A. Daverio 1; M. Borsali 1; K. Trabelsi 1; L. Agrigoroaie 1; D. Deandreis 1; C. Garcia 1
|